University of Charleston
Kristy Lucas
Contact Info

kristylucas@ucwv.edu

304-357-4363

Associate Dean of Academic Affairs

  • Doctor of Pharmacy, Campbell University School of Pharmacy
  • Residency in Clinical Pharmacy Practice, Charleston Area Medical Center

  1. November 2011 – present“Effects on Warfarin Dosage Requirements After Anticoagulation Therapy with Dabigatran” Investigators: B. Brubaker, K. Lucas
  2. August 2011 – present “Does Implementation of Active Learning Correlate with Increased Retention  of Material During the P4 Year?”  Investigators: A. Kimble, M. Hoyland, J. Testman, M .Euler, K. Lucas.
  3. August 2010 – 2011  Faculty Attitudes toward Teaching Survey Investigators: K.Lucas, M. Bottorff, S. Bowles, M. Hoyland, A.Kimble, T.White
  4. June 2010 – January 2011BI – TTR Study (A Retrospective Study to Assess the Quality of Anticoagulation with Warfarin in Patients with Nonvalvular Atrial Fibrillation)  Local Principle Investigator: William Carter, MD, Co-Investigator and Study Coordinator: K. Lucas, Pharm.D.  Supported by Boehringer Ingelheim via Duke University Cooperative Cardiovascular Society and Duke Clinical Research Institute and CAMC Health Education and Research Institute
  5. October 2009 – 2010 High Sensitivity C-Reactive Protein Value in Guiding Statin Therapy in a Primary Prevention Population Investigators: K. Lucas Pharm.D., BD Lucas Pharm.D., M Broce MS Supported by CAMC Health Education and Research Institute
  6. January 2007 – 2008Does Perioperative Nonsteroidal Anti-inflammatory Drug Use During Coronary Artery Bypass Grafting Increase Cardiovascular Events? Principle Investigators: K. Lucas Pharm.D.,, Bernardo Reyes, MD Co-Investigators:  Santos RD, Ayoubi M, Broce M, and Lucas BD.  Supported by CAMC Health Education and Research Institute.
  7. March 2006 – January 2007    Does Ejection Fraction Less than 50% Predict Stroke in Women Undergoing Coronary Artery Bypass Grafting? Principle Investigator:  Bernardo Reyes, MD Co-Investigators:  Dorairajan S, Broce M, Davis E, Lucas BD, Elhabyan AK, Iden L, and Lucas KH.  Supported by CAMC Health Education and Research Institute
  8. June 2005 – 2006 “Brain Natriuretic Peptide in Acutely Decompensated Chronic Heart Failure”  Principle Investigators: Heather Ratliff DO and Gregory Clarke MD.  Co-Investigators: Mohammed Yousufuddin MD, K. Lucas Pharm.D., Jennifer Adkins MSIV.       Supported by CAMC Health Education and Research Institute
  9. June 2003 – 2004       “A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study On Extended VTE Prophylaxis in Acutely Ill Medical Patients with Prolonged Immobilization (EXCLAIM trial).” Principle Investigator: Robert Touchon, MD; Co-Investigator: K. Lucas, PharmD.  Study Pharmacist: K. Lucas, PharmD, Sponsor:  Aventis Pharmaceuticals, Inc.  Grant Award:  $80,000
  10. June 2003 – 2004       “The Dose Response of Niacin ER/Lovastatin on Peak Walking Time in Patients with Intermittent Claudication – a Matrix Design (TROPIC study)” Principle Investigator:  Robert Touchon, MD; Co-Investigators: K. Lucas, PharmD, Greg Rosencrance, MD; Sponsor:  Kos Pharmaceuticals, Inc. Grant Award:  $200,000
  11. June 2003 – 2004 “A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients with Hypercholesterolemia.” Principle Investigator:  Robert Touchon, MD; Co-Investigators: K. Lucas, PharmD, Stephen Grubb, MD, Greg Rosencrance MD. Sponsor:  Merck & Co.  Grant Award: $37,680
  12. June 2003 – 2004 “An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke.” Principle Investigator:  Robert Touchon, MD; Co-Investigators: K. Lucas, PharmD, Greg Rosencrance, MD. Sponsor:  Aventis Pharmaceuticals, Inc.
  13. January 2003 – 2004  “A Multicenter, Randomized, Controlled trial comparing the safety and effectiveness of Surfaxin delivered via bronchopulmonary segmental lavage to standard of care in patients with acute respiratory distress syndrome (ARDS).” Principle Investigator:  Kurt Nelhaus, MD Study Pharmacist: K. Lucas, PharmD; Sponsor:  Discovery Laboratories, Inc.
  14. June 2002 – May 2004     “Accessible Intelligent Medications Strategies (AIMS) – An Academic Detailing Pilot Program for Enhancing Pharmaceutical Use in West Virginia.”  Principle Investigator:  Suresh Madhavan Ph.D., Co-investigators: S. Small, R.Ph., K. Bochna R.Ph., T. Dunsworth, Pharm.D., C. Terpening, Ph.D., Pharm.D., K. Lucas, Pharm.D., B Hodges, PharmD., D. Slain, Pharm.D., T. Whetsel, Pharm.D., J. Kavookjian, Ph.D., M.Smith, Ph.D. Funding:  $428,099/yr from West Virginia Public Employees Insurance Agency
  15. December 2001 – January 2003   “Using Telemedicine to Manage Heart Failure Patients”  Principle Investigator: G. Rosencrance, M.D., Co-Investigators:  K. Lucas, Pharm.D., B. McKee, RN,  H. Baker, Pharm.D., D. Rollins, Pharm.D., MB Schloss, Pharm.D. Supported by CAMC Health Education and Research Institute
  16. October 2001 – October 2002 “Readiness to Change Model Applied to Guideline Adherence”  Principle Investigator:  D. Bell, Pharm.D., Co-Investigators:  M. Amonkar, Ph.D., J. Kavookjian, Ph.D., K. Lucas, Pharm.D., C. Terpening, Pharm.D.,Ph.D. Submitted: National Institutes of Health National Heart Lung and Blood Institute; not funded
  17. June 2001 – August 2001 “Pre-Game:  A Pilot Project of the Getting Adults More Exercise Study”  Principle Investigator:  J. Fuscaldo, M.D., Co-Investigator:  K. Lucas, Pharm.D. Research support provided by Summer Research Externship Program of Charleston Area Medical Center Health and Education Research Institute
  18. October 2000 – August 2002   “Getting Adults More Exercise” (GAME Study) Principle Investigator:  J. Fuscaldo, M.D., Co-Investigator:  K. Lucas, Pharm.D. Submitted:  American Heart Association, Robert Wood Johnson Foundation; not funded
  19. September 2000 – 2003  “Assessment of Immunization Policies & Practices in WV Long-Term Care Facilities”  Co-Principle Investigators:  D. Elliott, Pharm.D., K. Lucas, Pharm.D.  Funding:  $7,808.58 and research support personnel  Source:  CAMC Health Education and Research Institute
  20. October – December 2000“Clinical Pharmacy Intervention Program:  One year outcomes”  Mentored Research Fellow:  M. Miller, Pharm.D.  Mentored Pharmacy Practice Resident: D. Hutson, Pharm.D.
  21. October 1999 – September 2000  “Establishing the Role of Clinical Pharmacy in an Ambulatory Care Medicine Clinic”   Mentored Pharmacy Practice Resident:  K. Gum, Pharm.D.
  22. January 1998   “Assessing the use of Dietary Supplements in Prescription Drug Using Populations”  Principle Investigator:  K. Holmes Lucas, Pharm.D. Candidate Advanced Community Pharmacy Research Project

Publications

Peer Reviewed Journals:

  1. Warwick T, Kali M, Carter W, Lucas KH, Masood S, Dawli R, Broce M, Reyes BJ.  Effect of Neurology Consults on Outcomes in Patients Suffering TIAs after Coronary Artery Bypass Grafting.  American Journal of Medical Quality 2008;23:457-464.
  2. Warwick TC, Moningi V, Jami P, Lucas KH, , Molokwu O, Shalini Moningi.  Neuroleptic Malignant Syndrome Variant in a Patient Receiving Donepezil and Olanzapine.  Nature Clinical Practice Neurology  2008;4(3):170-4.
  3. Lucas BD, Lucas KH, and Reyes BJ.  Alternative Viewpoints: More on NSAIDS and Cardiovascular Risk. Pharmacotherapy 2007:27:e7-e8.
  4. Lucas BD, Lucas KH, Reyes BJ.  Cardiovascular Risks of Cyclooxygenase Inhibition.  Pharmacotherapy  2006;26e125-e128.
  5. Lucas KH.  The Interaction of CAM and Prescription Heart Medications.  US Pharmacist 2006;8:66-76.
  6. Lucas KH, Terpening CM, Elliott DP.  Regarding the Management of Persistent Pain in Older Persons The Journal of the American Geriatrics Society 2003;51(7):1045.
  7. Lucas KH.  Herbal Products:  Pearls, Perils, and Precautions for the Prescriber.  The Female PatientA Peer- Reviewed Journal 2002;27(12):34-38.
  8. Lucas BD, Elhabyan AK, Lucas KH.  Rationale for Increasing the Starting Dose of Simvastatin.  Clinical Drug Investigation and Drugs in Research and Development 2002;22(9):639-40.
  9. Lucas KH.  Book Reviews:  Evidence-based Pharmacy.  American Journal of Pharmaceutical Education 2001;65:104.
  10. Metz CA, Lucas KH.  Alternate-Day Dosing of HMG-CoA Reductase Inhibitors for Cholesterol Reduction. The Annals of Pharmacotherapy 2001;35(4):496-500.
  11. Lucas KH, Kaplan-Machlis B.  Orlistat:  A novel weight loss therapy. The Annals of Pharmacotherapy 2001;35(3):314-328.(ACPE Universal Program Number 407-000-01-008-H01)
  12. Tomblin FA, Lucas KH.  Alternate Therapies:  Lysine for management of herpes labialis. American Journal of Health-System Pharmacy 2001;58:298-304.
  13. Lucas KH, Kaplan-Machlis B.  More About Orlistat.  Pharmacotherapy 2000;20(7):872-873.
  14. Lucas KH, Schliesser SH, and O’Neil MG.  Shaking, Chills, and Rigors with Once-Daily Gentamicin. Phamacotherapy 1999;19(9):1102-1104.
  15. Lucas KH, Davis SM.  Calcium in Corticosteroid-Induced Osteoporosis.  The Annals of Pharmacotherapy. 1998;32(9):970-2.
  16. Peer Reviewed Texts
  17. 2014 Lippincott’s Nursing  Drug Guide.  Lippincott Williams & Wilkins.  2012 Lucas KH, reviewer and contributor to approximately 80 drug monographs.
  18. Nursing 2011 Drug Handbook.  31st Edition.  Lippincott Williams & Wilkins.  2009  Lucas KH, updated therapeutic section:  hormonal drugs
  19. Nursing 2009 Drug Handbook. 29th Edition.  Wolters Kluwer / Lippincott Williams & Wilkins.  2008 Lucas KH, updated therapeutic section:  hormonal drugs.
  20. Dental Drug Reference with Clinical Implications.  Pickett FA and Terezhalmy GT. Baltimore, MD.  Lippincott Williams & Wilkins.  2006 Lucas KH, editorial board member and contributor.
  21. Nursing 2003 Drug Handbook.  Springhouse, PA:  Springhouse Corp., 2003 Lucas KH, author of monograph and patient teaching aid:  NuvaRing
  22. Nursing 2002 Drug Handbook.  Springhouse, PA:  Springhouse Corp., 2002. Lucas KH, author of monograph and patient teaching aid:  Foradil
  23. Nursing Herbal Drug Handbook.  Springhouse, PA:  Springhouse Corp., 2001. Lucas KH, author of monographs:  Acacia gum, Acidophilus, Aconite, Agar, Agrimony Lucas KH, author of appendix:  Drug-Herb Interactions
  24. Nursing 2001 Drug Handbook.  Springhouse, PA:  Springhouse Corp., 2001 Lucas KH, author of monographs and patient teaching aids:  Lotronex, Sarafem

Abstracts

  1. Brubaker B and Lucas KH.  Effects on Warfarin Dosage Requirements after Anticoagulation Therapy with Dabigatran. 2012 American College of Clinical Pharmacy Annual Meeting.  Hollywood, Florida. October 24, 2012. (Poster ID:  #443)
  2. Kimble A, Hoyland M, Testman J,Euler M, Lucas KH. Does Implementation of Active Learning Correlate With Increased Retention of Material During the P4 Year? Am J Pharm Educ 2012;76(5)Article 99:29-30.  American Academy of Colleges of Pharmacy Annual Meeting. Hollywood, FL July 2012.
  3. Lucas KH, Lucas, Jr. BD, and Broce M.  High Sensitivity C-Reactive Protein Value in Guiding Statin Therapy in a Primary Prevention Population.  American College of Clinical Pharmacy Spring Practice and Research Meeting. Charlotte, NC.  April 26, 2010 (Poster ID: PII-10)
  4. Lucas KH, Reyes BJ, Santos RD, Ayoubi M, Broce M, and Lucas BD.  Nonsteroidal Anti-inflammatory Drugs During Coronary Artery Bypass Grafting Does Increase Cardiovascular Events.  Clinical Pharmacology &Therapeutics 2008;83(1):S44. Presented at American Society for Clinical Pharmacology and Therapeutics 2008 Annual Meeting, Orlando, FL. April 4, 2008. (Poster ID:PII-06)
  5. Warwick TC, Jami P, Lucas KH, Moningi V, Reyes BJ.  A Case of Neuroleptic Malignant Syndrome Induced by Donepezil and Olanzapine.  Presented at CAMC Health Education and Research Institute & RCB Health Sciences Center/Charleston Division Research Day. April 11, 2006.  Charleston, WV.
  6. Lucas KH, McKee B, Baker H, Rollins D, Schloss M, Rosencrance J.  A New Role for Pharmacists? Using In-Home Telemonitoring Devices to Manage Heart Failure Patients.  Accepted for podium presentation by the APhA – APPM section at the American Pharmacists Association 2005 Annual Meeting, Orlando Florida, April 2, 2005.
  7. Roy AN, Roy S, Madhavan SS, Bochna K, Joseph F, Huffman K, Hodges B, Dunsworth T, Lucas KH, Terpening C, Kavookjian J, Ogershok O, Whetsek T.  Implementation and Early Impact Assessment of an ‘Academic Detailing’ Program, accepted for presentation by the APRS-EMMS section at the American Pharmacists Association 2005 Annual Meeting, Orlando Florida, April 1-5, 2005.
  8. Roy A, Roy S, Madhavan S, Bochna K, Bowyer D, Moorehead B, Terpening C, Lucas KH, Whetsel T, Dunsworth T, Ogershok P.  Assessment of physician satisfaction with Academic Detailing in two cities in West Virginia. Podium presentation at the Midwest Pharmacy Administration Meeting, Purdue University, July 29-31, 2004. West Lafayette, IN
  9. Roy S, Roy A, Madhavan S, Bochna K, Susman T, Joseph F, Hodges B, Dunsworth T, Lucas KH, Terpening C, Kavookjian J, Ogershok P, Whetsel T.  Assessment of the Impact of Academic Detailing in PromotingGeneric Drug Prescribing Among Ambulatory Care Physicians in West Virginia. Presented at ISPOR 9th Annual International Meeting, May 16-19, 2004. Arlington, VA
  10. Roy A, Roy S, Madhavan S, Bochna K, Bowyer D, Moorehead B, Terpening C, Lucas KH, Whetsel T, Dunsworth T, Ogershok P.  Impact of Academic Detailing in Promoting Rational Cost-Effective Prescribing Behavior Among Primary Care Physicians in West Virginia – encouraging preliminary results.  Presented at American Public Health Association meeting.  Washington DC.  November 2004.
  11. Casdorph D, Kavookjian J, Whetsel T, Lucas KH.  Evaluation of the use of Drug Cards as a Learning Tool in Nonprescription Drug Course.  Presented at American Association of Colleges of Pharmacy meeting. Salt Lake City, Utah.  July 2004
  12. McKee BR, Monk MD, Baker H, Lucas KH, Rollins D, Rosencrance JG, Schloss MB.  Using Telemedicine to Manage Heart Failure Patients.  Presented at the 2002 Nursing Research Conference Nursing Research for Practice:  Past, Present, and Future.  White Sulphur Springs, West Virginia, November 2002
  13. Lucas KH, McKee B, Baker H, Rollins D, Schloss MB, Rosencrance JG.  Using Telemedicine to Manage Heart Failure Patients.  The Journal of Heart Failure 2002;7(1):80.  Presented at the International Academy of Cardiology 8th World Congress on Heart Failure, Washington D.C., July 16, 2002
  14. Metz C, Lucas KH.  Significant Interaction Between Clarithromycin and Warfarin in a Patient with Antiphospholipid Antibody Syndrome.  Presented at the 35th Annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists, Las Vegas, NV, December 2000
  15. Metz C, Lucas KH.  Significant Interaction Between Clarithromycin and Warfarin in a Patient with Antiphospholipid Antibody Syndrome.  Presented at West Virginia University / Charleston Area Medical Center Annual Resident Research Day Conference, Charleston, WV, April 2000
  16. Lucas KH.  Assessing Use of Dietary Supplements in Prescription Drug Using Populations. Presented at West Virginia University / Charleston Area Medical Center Annual Resident Research Day Conference, Charleston, WV, April 1999
  17. Lucas KH, Schliesser SH, O’Neil MG.  Shaking, Chills, Rigors with Once-Daily Gentamicin. Presented at West Virginia University / Charleston Area Medical Center Annual Resident Research Day Conference, Charleston, WV, April 1999

Non-Peer Reviewed

  1. Bowyer D and Lucas KH. Legislative Issues Related to Pharmacy. West Virginia Society of Health-System Pharmacists Newsletter.  February 2011.
  2. Elswick BM and Lucas KH.  Collaborative Practice Update.  West Virginia University School of Pharmacy’s Showglobe.  Spring edition 2004.
  3. Editor-in-Chief of State-wide Newsletter:  New Drug Update, November 2000 – December 2007 Mailed to 400+ prescribers in West Virginia and surrounding areas.
    1. Waldorf C, Griffith JP, and Lucas KH.  Invega (paliperidone) New Drug Update. 2007;13(3):1-4.
    2. Fought J, Lucas KH, and Griffith JP.  Rozerem (ramelteon) New Drug Update. 2007;13(2):1-3.
    3. Mitchell B, Lucas KH, and Newbrough MA. Zostavax (zoster vaccine) New Drug Update.2007;13(2):4-6.
    4. Connolly A, Hanlon C, and Lucas KH.  Ranexa (Ranolazine) New Drug Update. 2007;13(1):1-4.
    5. Chaney M, Lucas KH, and Pfister A.  Orencia (Abatacept) New Drug Update. 2007;13(1):4-6.
    6. Francis K and Lucas KH.  Omacor (omega-3-acid ethyl esters)  New Drug Update. 2006;12(3):4-6.
    7. Paul C and Lucas KH.  Lyrica (pregabalin)  New Drug Update. 2006;12(3):1-4.
    8. Price C and Lucas KH.  Campral (acamprosate)  New Drug Update. 2006;12(2):4-6.
    9. Ellis W and Lucas KH.  VESIcare (solifenacin)  New Drug Update. 2006;12(2):6-8.
    10. Bay K and Lucas KH.  Elistat (epinastine)  New Drug Update. 2006;12(1):6-8.
    11. Whittington R and Lucas KH.  Sensipar (cinacalcet)  New Drug Update. 2006;12(1):4-6.
    12. Hanchock D, Lucas KH, and Jami P.  Byetta (exenatide)  New Drug Update. 2006;12(1):1-4.
    13. DeRito A, Lucas KH and Levien J.  Aloxi (palonosetron) New Drug Update. 2005;11(3):1-4.
    14. Maynor L and Lucas KH.  Ertaczo (sertaconazole) New Drug Update. 2005;11(3):4-6.
    15. Price J, Riser N, and Lucas KH.  Boniva (ibandronate) New Drug Update. 2005;11(2):3-6.
    16. Fryer J, Lucas KH and Jami P.  Enablex (darifenacin) New Drug Update. 2005;11(2):1-3.
    17. Ball N and Lucas KH.  Cymbalta (duloxetine) New Drug Update. 2005;11(1):5-8.
    18. Walbrown M and Lucas KH.  Xolair (omalizumab) New Drug Update. 2004;10(4):1-4.
    19. Ferro M and Lucas KH.  Uroxatral (alfuzosin) New Drug Update. 2004;10(4):4-6.
    20. Veltry L and Lucas KH.  Humira (adalimumab) New Drug Update. 2004;10(2):4-8.
    21. Stroupe A and Lucas KH.  Oxytrol (oxybutynin) New Drug Update. 2004;10(1):4-6.
    22. Cardona K and Lucas KH.  Crestor (rosuvastatin) New Drug Update. 2004;10(1):1-4.
    23. Hatfield M, Keck SW, and Lucas KH.  Subutex and Suboxone New Drug Update. 2003;9(6):3-6.
    24. Shanor C and Lucas KH.  FluMist (influenza vaccine live) New Drug Update. 2003;9(6):1-3.
    25. Hare J and Lucas KH.  Emend (aprepitant) New Drug Update. 2003;9(5):6-8.
    26. Samples B and Lucas KH.  Forteo (teriparatide) New Drug Update. 2003;9(5):3-5.
    27. Stollings J and Lucas KH.  Tracleer (bosentan) New Drug Update. 2003;9(4):6-8.
    28. Latocha M and Lucas KH.  Abilify (aripiprazole) New Drug Update. 2003;9(4):1-3.
    29. Bazzie K and Lucas KH.  NuvaRing (etonogestrel/ethinyl estradiol) New Drug Update. 2003;9(3):6-8.
    30. Dolin D and Lucas KH.  Strattera (atomoxetine) New Drug Update. 2003;9(3):3-6.
    31. McCoy M and Lucas KH.  Benicar (olmesartan) New Drug Update. 2003;9(2):4-6.
    32. Johnson E and Lucas KH.  Zelnorm (tegaserod) New Drug Update. 2003;9(2):6-8.
    33. Surface T and Lucas KH.  Elidel (pimecrolimus) New Drug Update. 2003;9(1):4-6.
    34. Lykins B and Lucas KH.  Advicor (niacin ER / lovastatin) New Drug Update. 2003;9(1):1-3.
    35. Jones J and Lucas KH.  Xyrem (sodium oxybate) New Drug Update. 2002;8(9):4-6.
    36. Miller R and Lucas KH.  Frova (frovatriptan) New Drug Update. 2002;8(9):1-3.
    37. Moles C and Lucas KH.  Clarinex (desloratadine) New Drug Update. 2002;8(5):4-6.
    38. Staples S and Lucas KH.  Ortho Evra New Drug Update. 2002;8(5):1-3.
    39. Strow J and Lucas KH.  Foradil (formoterol fumarate) New Drug Update. 2002;8(4):3-6.
    40. Powell P and Lucas KH.  Vaniqa (eflornithine hydrochloride) New Drug Update. 2002;8(3):1-3.
    41. Conners C and Lucas KH.  Advair (salmeterol / fluticasone) New Drug Update. 2002;8(3):3-6.
    42. Hall A and Lucas KH.  Penlac (ciclopirox) New Drug Update. 2002;8(2):4-6.
    43. Richmond C and Lucas KH.  Axert (almotriptan) New Drug Update. 2002;8(1):4-6.
    44. Simmons L and Lucas KH.  Keppra (levetiracetam) New Drug Update. 2002;8(1):1-4.
    45. Mong K and Lucas KH.  Nexium (esomeprazole) New Drug Update. 2001;7(5):1-4.
    46. Elliott D and Lucas KH.  Geodon (ziprasidone) New Drug Update. 2001;7(5):4-6.
    47. Tomblin F and Lucas KH.  Visicol (sodium phosphate) New Drug Update. 2001;7(4):4-6.
    48. Flowers K and Lucas KH.  Welchol (colesevelam) New Drug Update. 2001;7(3):4-6.
    49. Spence J and Lucas KH.  Lantus (insulin glargine) New Drug Update. 2001;7(3):1-4.
    50. Brula A and Lucas KH.  Mobic (meloxicam) New Drug Update. 2001;7(2):4-6.
    51. Spence C and Lucas KH.  Protonix (pantoprazole sodium) New Drug Update. 2001;7(1):4-6.
    52. McDermitt B and Lucas KH.  Actonel (risedronate sodium) New Drug Update. 2001;7(1):1-4.
    53. Jones R and Lucas KH.  Exelon (rivastigmine tartrate) New Drug Update. 2000;6(6):1-3.
    54. Boothe WH and Lucas KH.  Trileptal (oxcarbazepine) New Drug Update. 2000;6(6):3-5.
    55. Lucas KH and Kaplan-Machlis B.  Singulair (montelukast sodium) New Drug Update. 1999;5(3):1-3.
  4.  Holmes KK.  Local Presentations Start Year for Student Society of Health-System Pharmacy (SSHP). NCSHPNewsletter, 1996;19(5):6.
  5. Holmes KK.  SSHP Elects New Officers.  NCSHP Newsletter, 1996;19(1):6.
  6. Holmes KK.  Student Society of Health-System Pharmacy Update. Campbell Comments, Winter 1996;9(1):6.
  7. Holmes KK.  Campbell’s SSHP New in N.C.  NCSHP Newsletter, 1996;18(5):8.

Reviewing Activities

  1. Pharmacotherapy
  2. American Journal of Health-System Pharmacists
  3. Journal of Clinical Research
  4. The Annals of Pharmacotherapy  
  5. The Consultant Pharmacist
  6. Journal of Women’s Health and Gender-Based Medicine
  7. Journal of the American Pharmaceutical Association
  8. American Journal of Pharmaceutical Education.
  9. Springhouse / Lippincott Williams & Wilkins Corporation
  10. Handbook of Nonprescription Drugs:  An Interactive Approach to Self-Care 14th edition.

Kristy Lucas, Pharm.D., FCCP is a Professor of Pharmacy Practice at the University of Charleston School of Pharmacy.  She also holds an Adjunct Associate Professor appointment with the WVU School of Medicine. She served as Interim Department Chair for the UCSOP Pharmacy Practice Department from 2011-2012.  Her current practice serves patients in the ambulatory care setting, primarily focused on anticoagulation, hyperlipidemia and general cardiovascular risk reduction.  Dr. Lucas held dual academic appointments as an Associate Professor in the Schools of Pharmacy and Medicine of West Virginia University’s Charleston campus for over ten years.    Dr. Lucas graduated from Campbell University School of Pharmacy in North Carolina and completed a Residency in Clinical Pharmacy Practice at Charleston Area Medical Center.

Dr. Lucas is a past President of West Virginia Society of Health-System Pharmacists.  She has also served as Secretary and Board Member at Large for WVSHP.  She has been active in the American College of Clinical Pharmacy, the American Society of Health-System Pharmacists, American Pharmacists Association, American Society for Clinical Pharmacology and Therapeutics, and the American Heart Association. She has served on national committees for ACCP and ASHP.  Dr. Lucas has been appointed to serve on committees for the West Virginia Department of Health and Human Resources by the Governor of WV. She served as a member of the West Virginia University / Charleston Area Medical Center Institutional Review Board for many years.  She served as co-chair of the Task Force for Collaborative Pharmacy Practice in WV, as an advisor for the West Virginia Board of Pharmacy regarding finalizing regulations for collaborative pharmacy practice and immunization legislation, in addition to the modernization of the WV Pharmacy Practice Act in 2013.  She has been active in the West Virginia Alliance for Pharmacists Care and she maintains activity in assisting with annual statewide legislative agendas and efforts on behalf of the profession of pharmacy.  She currently serves on the WV Board of Pharmacy Continuing Education Committee. In 2015, Dr. Lucas was inducted as a Fellow of the American College of Clinical Pharmacy.  She was awarded the West Virginia Society of Health System Pharmacists Pharmacy Leadership Award in 2004 for legislative efforts on behalf of pharmacy.  She also received the Bristol-Myers Squibb Pharmacy Leadership Award in 2003.  She was honored with the 2011 WVSHP Distinguished Educator Award and the 2013 P2 Teacher of the Year at UC School of Pharmacy.  She has been inducted as a member of Rho Chi Pharmaceutical Honor Society, Phi Lambda Sigma Pharmacy Leadership Society, as well as Who’s Who in Pharmaceutical Sciences Education. She has published over 15 peer-reviewed articles and has myriad research endeavors and presentations to her credit.